Global Ophthalmology Drugs Industry : Market Status, Size, Share, Trends and Application 2017
ResearchMoz presents professional and in-depth study of "Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape". Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness. The patents protecting the three most commercially successful products, all marketed in wet AMD, are expected to expire in the coming years - Lucentis (ranibizumab) and Avastin (Bevacizumab) in 2018, and Eylea (aflibercept) in 2020. However, revenue from anticipated new approvals such as lampalizumab in dry AMD, Fovista (pegpleranib sodium) in wet AMD...